Your browser doesn't support javascript.
loading
Probabilistic disease progression modeling to characterize diagnostic uncertainty: Application to staging and prediction in Alzheimer's disease.
Lorenzi, Marco; Filippone, Maurizio; Frisoni, Giovanni B; Alexander, Daniel C; Ourselin, Sebastien.
Afiliação
  • Lorenzi M; Asclepios Research Project, Université Côte d'Azur, Inria, France; Translational Imaging Group, Centre for Medical Image Computing, University College London, UK. Electronic address: marco.lorenzi@inria.fr.
  • Filippone M; EURECOM, France. Electronic address: maurizio.filippone@eurecom.fr.
  • Frisoni GB; Geneva Neuroscience Center, University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli, Brescia, Italy. Electronic address: Giovanni.Frisoni@unige.ch.
  • Alexander DC; POND Group, Centre for Medical Image Computing, University College London, UK. Electronic address: d.alexander@ucl.ac.uk.
  • Ourselin S; Translational Imaging Group, Centre for Medical Image Computing, University College London, UK. Electronic address: s.ourselin@ucl.ac.uk.
Neuroimage ; 190: 56-68, 2019 04 15.
Article em En | MEDLINE | ID: mdl-29079521
ABSTRACT
Disease progression modeling (DPM) of Alzheimer's disease (AD) aims at revealing long term pathological trajectories from short term clinical data. Along with the ability of providing a data-driven description of the natural evolution of the pathology, DPM has the potential of representing a valuable clinical instrument for automatic diagnosis, by explicitly describing the biomarker transition from normal to pathological stages along the disease time axis. In this work we reformulated DPM within a probabilistic setting to quantify the diagnostic uncertainty of individual disease severity in an hypothetical clinical scenario, with respect to missing measurements, biomarkers, and follow-up information. We show that the staging provided by the model on 582 amyloid positive testing individuals has high face validity with respect to the clinical diagnosis. Using follow-up measurements largely reduces the prediction uncertainties, while the transition from normal to pathological stages is mostly associated with the increase of brain hypo-metabolism, temporal atrophy, and worsening of clinical scores. The proposed formulation of DPM provides a statistical reference for the accurate probabilistic assessment of the pathological stage of de-novo individuals, and represents a valuable instrument for quantifying the variability and the diagnostic value of biomarkers across disease stages.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Progressão da Doença / Doença de Alzheimer / Disfunção Cognitiva / Modelos Neurológicos Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Progressão da Doença / Doença de Alzheimer / Disfunção Cognitiva / Modelos Neurológicos Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article